First-Line Lorlatinib Versus Crizotinib in ALK-Positive NSCLC: Japanese Subgroup Analysis of CROWN

INTRODUCTION: Lorlatinib, a third-generation ALK inhibitor, was found to have improved efficacy versus crizotinib in patients with previously untreated, advanced ALK-positive NSCLC in the ongoing, global, randomized, phase 3 CROWN study. METHODS: The study’s primary end point was progression-free su...

Descripción completa

Detalles Bibliográficos
Autores principales: Hayashi, Hidetoshi, Teraoka, Shunsuke, Goto, Yasushi, Kumagai, Toru, Nishio, Makoto, Sugawara, Shunichi, Oizumi, Satoshi, Matsumura, Masakazu, Okura, Masayuki, Peltz, Gerson, Kato, Terufumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10050766/
https://www.ncbi.nlm.nih.gov/pubmed/37007870
http://dx.doi.org/10.1016/j.jtocrr.2023.100471

Ejemplares similares

Ejemplares similares